Leukemia Research
Volume 25, Issue 9 , Pages 741-747 , 1 September 2001

Dysplastic versus proliferative CMML – a retrospective analysis of 91 patients from a single institution

Received 2 December 2000 ,Accepted 30 December 2000.

References 

  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al.  Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology. 1982;51:189–199
  2. Verhoef GE, Pittaluga S, De Wolf-Peeters C, Boogaerts MA. FAB classification of myelodysplastic syndromes: merits and controversies. Annals of Hematology. 1995;71:3–11
  3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton D, Gralnick H, et al  The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukemia. proposals by the FAB cooperative leukaemia group. British Journal of Haematology. 1994;87:746–754
  4. Michaux JL, Martiat P. Chronic myelomonocytic leukemia (CMML). A myelodysplastic or myeloproliferative syndrome?. Leukemia and Lymphoma. 1993;9:35–41
  5. Storniolo AM, Moloney WC, Rosenthal DS, Cox C, Bennett JM. Chronic myelomonocytic leukemia. Leukemia. 1990;4:766–770
  6. Fenaux P, Beuscart R, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. Journal of Clinical Oncology. 1988;6:1417–1424
  7. Solal-Celigny P, Desaint B, Herrera A, Chastang C, Amar M, Vroclans M, et al.  Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases. Blood. 1984;63:634–638
  8. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al.  World Health Organization of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting–airlie house, virginia, november 1997. Journal of Clinical Oncology. 1997;17(12):3835–3849
  9. Schweizer D. Counterstained enhanced chromosome binding. Human Genetics. 1981;57:1–14
  10. Mitelman F. (Ed.), ISCN: an international system for human cytogenetic nomenclature. Basel: Karger, 1995.
  11. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. British Journal of Haematology. 1985;59:425–433
  12. Worsley A, Oscier DG, Stevens J, Darlow S, Figes A, Mufti GJ, et al.  Prognostic features of chronic myelomonocytic leukemia: a modified Bournemouth score gives the best prediction of survival. British Journal of Haematology. 1988;68:17–21
  13. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6:52–59
  14. Morel P, Hebbar M, Lai JL, Duhamel A. Cytogenetic analysis has strong prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia. 1993;7:1315–1323
  15. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  16. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. Journal of the American Statistical Association. 1958;53:457–481
  17. Cox DR. Regression models and life tables. J R Statistical Society. 1972;34:187
  18. Pfeilstöcker M, Reisner R, Nösslinger T, Grüner H, Nowotny H, Tüchler H, et al.  Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. British Journal of Haematology. 1999;106:455–463
  19. Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML-dysplastic versus proliferative type. Leukemia Research. 1998;22:871–878
  20. Heaney ML, Golde DW. Myelodysplasia—review article. The New England Journal of Medicine. 1999;340(21):1649–1660
  21. Beran M, Kantarjian H, O'Brien S, Koller C, Al-Bitar M, Arbuck S, et al.  Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 1996;88:2473–2479
  22. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. British Journal of Haematology. 1997;99:699–705
  23. Jonasova A, Neuwirtova R, Cermak J, Vozobulova V, Mocikova K, Siskova M, et al.  Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. British Journal of Haematology. 1998;100:304–309
  24. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high risk myelodysplastic syndrome. Leukemia. 1997;11:1–5
  25. Geissler K, Öhler L, Födinger M, Virgolini I, Leimer M, Kabrna E, et al.  Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells. Journal of Experimental Medicine. 1996;184:1377–1384

PII: S0145-2126(01)00014-5

Leukemia Research
Volume 25, Issue 9 , Pages 741-747 , 1 September 2001

Article Tools

* Image Usage & Resolution